The epidemiology of human betaherpesvirus 5, also known as human cytomegalovirus or CMV is the study of the distribution and determinants of the infection and disease caused by this virus in human populations. Some of the main aspects of the epidemiology of CMV are:

• Prevalence: CMV is a ubiquitous virus that infects most people worldwide at some point in their lives. The prevalence of CMV infection varies depending on the geographic region, socioeconomic status, age, and exposure to risk factors. A thorough review and meta-analysis found that the global seroprevalence of CMV was estimated to be 83% in 2010, with higher rates in Africa (94%), Latin America (92%), and Asia (91%) than in Europe (68%) and North America (59%). The seroprevalence also increases with age, reaching over 90% in adults over 50.
• Transmission: CMV can be transmitted through various routes, such as contact with bodily fluids (saliva, urine, blood, semen, breast milk), transplacental infection from mother to fetus, organ transplantation, blood transfusion, sexual intercourse, and breastfeeding. The viral load affects the risk of transmission, the type and duration of exposure, the host’s immune status, and the donor or recipient.
• Pathogenesis: CMV can infect various cell types, such as epithelial cells, endothelial cells, fibroblasts, monocytes/macrophages, and lymphocytes. CMV can establish latent infection in some cells, such as monocytes/macrophages and hematopoietic stem cells, and reactivate under certain conditions, such as immunosuppression or inflammation. CMV can also evade or modulate the host immune response by expressing various proteins interfering with antigen presentation, cytokine production, complement activation, natural killer cell recognition, and apoptosis.
• A comprehensive research and meta-analysis revealed the global mortality rate of CMV in immunocompetent adults was estimated to be 0.06% in 2010, with higher rates in Africa (0.13%) and Asia (0.08%) than in Europe (0.03%) and North America (0.02%) However, Due to underreporting, these rates can be understated or misdiagnosis of CMV-related deaths.
• For those with impaired immune systems, such as HIV patients and organ transplant recipients, or cancer patients, the mortality rate of CMV can be much higher, ranging from 5% to 50%, depending on the type and extent of immunosuppression, the organ system involved, and the response to antiviral therapy. For example, CMV pneumonia is one of the most common and fatal opportunistic infections in AIDS patients, with a mortality rate of up to 80%.

•  Kingdom: Virus
• Phylum: Peploviricota
• Class: Herviviricetes
• Order: Herpesvirales
• Family: Orthoherpesviridae
• Genus: Cytomegalovirus
• Species: Human betaherpesvirus 5

The structure of human betaherpesvirus 5, also known as human cytomegalovirus or CMV, is a complex and fascinating topic. Here are five points that summarize the main features of this virus:

• Virus Structure: Human betaherpesvirus 5 is a double-stranded DNA virus with a protective capsid of 162 capsomeres. It is surrounded by a tegument layer containing viral proteins and a lipid envelope with glycoproteins for host cell entry.
• Genome and Genes: Its genome is about 230 kilobases long and encodes over 200 genes, many of which help the virus evade the host immune response. Genes are sections of DNA that include protein-coding or functional RNA.
• Alternative Names: Also referred to as human herpesvirus 5 (HHV-5), reflecting its similarity to other herpesviruses. Herpesviruses share standard features like double-stranded DNA genomes, icosahedral capsids, tegument layers, and lipid envelopes.
• Infection and Evolution: Human betaherpesvirus 5 is a member of the herpesvirus family, characterized by its capacity to spread infection and grow in host cells. Its taxonomic classification highlights its evolutionary relationships with other viruses in the hierarchy of viral groups.

• The gB family consists of four subtypes: gB1, gB2, gB3, and gB4. These subtypes are distributed worldwide and can be found in clinical and laboratory CMV strains. The gB subtypes mediate the joining of the viral envelope and host cell membrane and initiate the infection. The gB subtypes also elicit neutralizing antibodies to prevent or reduce the infection.
• The gH/gL family comprises two complexes: gH/gL/UL128/UL130/UL131A and gH/gL/UL128/gL/gO. These complexes bind to different host cell receptors and determine the CMV tropism for different cell types. The gH/gL/gO complex binds to heparan sulfate proteoglycans (HSPGs) and is essential for infecting fibroblasts and epithelial cells. The gH/gL/UL128/UL130/UL131A complex binds to platelet-derived growth factor receptor alpha (PDGFR-alpha) and EGFR, or epidermal growth factor receptor, is crucial for infecting endothelial cells and monocytes/macrophages. The gH/gL complexes also elicit neutralizing antibodies that can block the attachment and entry of CMV into host cells.
• The gM/gN family consists of two subtypes: gM1/gN1 and gM2/gN2. These subtypes are involved in the assembly and egress of CMV from host cells. The gM/gN subtypes also modulate the immune response by interfering with the natural killer (NK) cell recognition and complement activation. The gM/gN subtypes do not elicit neutralizing antibodies, but they may induce other types of immune responses, such as cellular immunity or antibody-dependent cellular cytotoxicity (ADCC).

The pathogenesis of Human betaherpesvirus 5 involves several key steps:

• Transmission: CMV is primarily transmitted through contact with physiological fluids such as blood, breast milk, urine, and saliva. Additionally, it can be passed from mother to fetus during pregnancy, via blood transfusion, and during organ transplantation.
• Entry and Primary Replication: After transmission, CMV infects mucosal epithelial cells at the entry site, such as the respiratory or genital tract. The virus then enters these cells and undergoes primary replication. The virus can also spread to monocytes, a type of white blood cell, allowing it to disseminate throughout the body.
• Latency and Latent Infection: CMV can establish latency after primary replication. During latency, the virus enters a dormant state within specific cells, especially monocytes and other immune cells. The viral genome persists in these cells but does not actively replicate, evading the immune system’s detection. Latency allows CMV to evade immune responses and reactivate later under certain conditions.
• Viral Reactivation: Periodically, CMV can reactivate from latency due to various factors, such as immunosuppression (e.g., due to stress, organ transplantation, HIV infection) or other illnesses. Reactivation involves the virus moving from latent to lytic replication, where it begins actively producing new virus particles.
• Lytic Replication and Spread: During lytic replication, CMV produces large numbers of viral particles that lyse (rupture) the host cell, releasing the new virus particles. It may result in tissue deterioration and inflammation at the site of infection. The virus can infect nearby cells and spread to other organs through the bloodstream.
• Tissue Damage and Clinical Manifestations: CMV infection can cause tissue damage and inflammation in various organs, leading to clinical manifestations. In healthy individuals, the immune response can usually control the infection, leading to mild or no symptoms. However, in immunocompromised individuals, CMV can cause severe diseases such as pneumonitis (lung inflammation), retinitis (eye inflammation), and gastrointestinal complications.
• Congenital Infection: CMV can also be transmitted from a pregnant mother to her fetus, leading to congenital CMV infection. It can result in developmental issues, hearing loss, and other complications in newborns.

• The host defenses against human betaherpesvirus 5 (CMV), including innate and adaptive immunity mechanisms. The human immune system employs a multi-faceted approach to combat CMV infection, involving various cell types, molecules, and pathways.
• The role of innate immunity, as you mentioned, is to provide an initial response to the viral invasion. Natural killer (NK) cells, dendritic cells, & macrophages play crucial roles in identifying and reacting to pathogens.
•  To CMV-infected cells and produce cytokines that orchestrate the immune response. Interferons and the complement system inhibit viral replication and enhance immune recognition.
• On the other hand, adaptive immunity involves more specialized responses that develop over time. B cells produce antibodies that can neutralize CMV particles and infected cells, and T cells recognize and eliminate infected cells through the MHC presentation of viral peptides. The distinction between CD4+ helper T cells and CD8+ cytotoxic T cells is also well-explained.
• CMV’s strategies to evade or modulate the immune response are crucial. CMV has evolved mechanisms to evade immune surveillance, such as interfering with MHC expression, cytokine receptors, and NK cell receptors. Establishing latency in specific cell types is another notable strategy, allowing CMV to hide from the immune system and reactivate later under certain conditions.

Human betaherpesvirus 5, also known as human cytomegalovirus or CMV, can cause various diseases in humans, depending on their immune status and the stage of infection. Some of the clinical manifestations of CMV infection are:

• Congenital CMV is when a pregnant woman, through the placenta, spreads the disease to her unborn child. Congenital CMV can cause severe congenital disabilities, such as microcephaly, hearing loss, vision loss, mental retardation, seizures, and death. Congenital CMV is the primary infectious factor that causes deafness and intellectual disability in children.
• Mononucleosis: This is when a person develops fever, sore throat, swollen glands, and fatigue after being infected with CMV. Mononucleosis is usually mild and self-limiting, but it can sometimes cause complications such as hepatitis, splenomegaly, hemolytic anemia, thrombocytopenia, and myocarditis.
• Pneumonia: This is when a person develops inflammation and infection of the lungs due to CMV. Pneumonia can cause cough, chest pain, shortness of breath, and hypoxia. Pneumonia is more common and severe in immunocompromised individuals, such as HIV patients, organ transplant recipients, or cancer patients.
• Retinitis is when a person develops inflammation and infection of the retina due to CMV. Retinitis can cause blurred vision, floaters, flashes, and blindness. Retinitis is more common and severe in immunocompromised individuals, especially those with AIDS.
• Colitis: This is when a person develops inflammation and ulceration of the colon due to CMV. Colitis can cause symptoms such as diarrhea, abdominal pain, bleeding, and weight loss. Colitis is more common and severe in immunocompromised individuals.
• Esophagitis is when a person develops inflammation and ulceration of the esophagus due to CMV. Esophagitis can cause dysphagia, odynophagia, chest pain, and bleeding. Esophagitis is more common and severe in immunocompromised individuals.
• Encephalitis: This is when a person develops inflammation and infection of the brain due to CMV. Encephalitis can cause symptoms such as headache, confusion, seizures, coma, and death. Encephalitis is more common and severe in immunocompromised individuals.

Diagnosing human cytomegalovirus (CMV) involves various tests:

• ELISA: Measures CMV antibodies in blood or fluids, showing past exposure but not active infection distinction.
• PCR: Amplifies and detects CMV DNA in blood, urine, etc., indicating active infection without details on severity or location.
• Antigenemia assay: Identifies CMV-infected cells in the blood, revealing high replication levels linked to severe disease.
• Viral culture: Grows and confirms CMV presence but takes time for results.

Control of human betaherpesvirus 5 (CMV) involves avoiding exposure through hygiene practices. It spreads through bodily fluids, so handwashing, not sharing items, using condoms, and avoiding close contact with infected individuals help. In severe cases, like in transplant or HIV patients, use antiviral drugs (e.g., ganciclovir, valganciclovir), but side effects and complete virus removal are challenges. Pregnant women get screened to prevent CMV transmission to the fetus, which can cause disabilities. There is no vaccine yet, but promising candidates in development could prevent widespread infections and disabilities.

• Human betaherpesvirus 5 – Wikiwand
• Human Cytomegalovirus – an overview | ScienceDirect Topics